spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  ThermoDox 

 HSMN NewsFeed - 23 Feb 2015
Celsion Announces Updated Overall Survival Data from HEAT Study of ThermoDox(R) in Primary Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jul 2014
Celsion Announces Updated Overall Survival Data from HEAT Study of ThermoDox(R) in Primary Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Feb 2014
Celsion Announces FDA Clearance of the OPTIMA Study - A Pivotal Phase III Trial of ThermoDox in Primary Liver Cancer
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 23 Apr 2013
Celsion Corporation Provides Business Update
Biopharmaceuticals Devices Drug Delivery Oncology
 HSMN NewsFeed - 25 Aug 2011
Celsion Announces the Appointment of Gary Renshaw, D.O., as Executive Medical Director
Devices Drug Delivery Oncology Personnel
 HSMN NewsFeed - 12 Jul 2011
Celsion Announces Management and Board Appointments
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Mar 2011
Celsion Receives European Orphan Drug Designation for ThermoDox(R) to Treat Primary Liver Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Feb 2011
Data Monitoring Committee Unanimously Recommends Continuation of Celsion's Phase III ThermoDox(R) HEAT Study to Treat Primary Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Oct 2010
Celsion Receives Positive FDA Guidance for its New Drug Application for ThermoDox(R) to Treat Primary Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Aug 2010
Celsion Receives Fast Track Designation for ThermoDox(R) Development Program to Treat Primary Liver Cancer
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 10 Feb 2010
Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jan 2010
Celsion Announces CFO Departure
Biopharmaceuticals Drug Delivery Oncology Personnel
 HSMN NewsFeed - 3 Jun 2009
Celsion Receives Final $15 Million Payment from Boston Scientific for Prolieve Assets Completing its Transition to a Drug Development Company
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Mar 2009
Celsion Receives Orphan Drug Designation for ThermoDox to Treat Primary Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Mar 2008
Celsion Commences Global Phase III Study for Primary Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Sep 2007
Celsion Bolsters Clinical Development Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jun 2007
Celsion Completes Sale of Prolieve Assets
Devices Acquisitions Urology
 HSMN NewsFeed - 18 Apr 2007
Celsion Announces Boston Scientific Exercises Its Option to Purchase Prolieve(R) Assets
Devices Urology Acquisitions
 HSMN NewsFeed - 14 Mar 2007
Celsion Expands Board, Appoints New Independent Director
Biopharmaceuticals Drug Delivery Oncology Personnel
 HSMN NewsFeed - 8 Feb 2007
Celsion and AMS Settle Patent Dispute
Devices Licensing Litigation
 HSMN NewsFeed - 21 Dec 2006
Celsion Corporation Announces New President/CEO
Devices Urology Personnel
 HSMN NewsFeed - 29 Sep 2006
Celsion Obtains from Valentis Exclusive Rights to Pegylation Patents for use with Heat Activated Liposomes
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 7 Sep 2006
Celsion Announces Management Changes and Formation of Prolieve and Oncology Divisions
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 7

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 7 additional stories matching:
ThermoDox
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.